Sirona Biochem To Present At BIO Asia And Received Over $1.1 Million Of Warrants Exercised

Vancouver, British Columbia – March 12, 2015 - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB), announces that its Chief Business Development Officer, Attila Hajdu, will be presenting at BIO Asia, March 24-25, 2015 in Tokyo, Japan. The Company’s CSO, Dr. Geraldine Deliencourt-Godefroy, will also be attending.

The BIO Asia International Conference, co-hosted by the Biotechnology Industry Organization (BIO), BioCentury and the Japan Bioindustry Association (JBA), brings together the global biotechnology and pharmaceutical industry to explore licensing and research collaborations in the current Asia-Pacific business and policy environments.

The conference is an exclusive, customized partnering forum featuring private, pre-arranged one-on-one meetings between senior-level executives, using BIO’s proprietary, state-of-the-art computer software. The format and selective nature of the conference makes this the premier dedicated biotech partnering event in Asia and an unrivaled opportunity to meet with the leading industry organizations in one place at one time.

The conference will provide an international stage for Sirona to present recently publicized results and partnering opportunities to leading pharmaceutical and biotech companies. Representation will include major organizations from both North American and Asia, including: Pfizer, Johnson & Johnson, Amgen, GSK, Daiichi Sankyo, Takeda, Eli Lily and many more. In 2014, nearly 40% of the 130 companies attending were Pharma companies.

Mr. Hajdu and Dr. Deliencourt-Godefroy will also be attending a number of additional meetings outside of the conference with cosmetic companies headquartered in the Tokyo area.

Warrants Exercised

Sirona Biochem is also pleased to announce that it has received $1,186,050 in cash on exercise of 7,907,000 warrants exercised at $0.15 per warrant. Each warrant was exercisable into one common share of the Corporation. The warrants had an expiration date of March 5, 2015. As of today, there are 138,030,490 shares issued and outstanding.

“The company is now in a strong cash position to continue the execution of its business plan and we look forward to announcing our commercialization successes in 2015”, commented Howard Verrico, CEO of Sirona Biochem.

For more information regarding this press release, please contact:

Christopher Hopton, CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064

About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety. Sirona Biochem’s compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem’s wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit

Help employers find you! Check out all the jobs and post your resume.

Back to news